More recently, in non-squamous NSCLC treated with a combination of platinum, pemetrexed and pembrolizumab, the STK11/LKB1 genomic alterations were associated with shorter PFS (mPFS 4.8 m versus 7.2 m, HR 1.5, 95% CI 1.1 to 2.0; p = 0.0063) and shorter OS (mOS 10.6 m versus 16.7 m, HR 1.58, 95% CI 1.09 to 2.27; p = 0.0083) compared with STK11/LKB1-wild type tumors [55]. Here, STK11 is linked to non-small cell lung carcinoma.